Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

by · The Cerbat Gem

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 6,950,000 shares, a decrease of 10.3% from the September 30th total of 7,750,000 shares. Based on an average daily volume of 899,400 shares, the days-to-cover ratio is presently 7.7 days.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GOSS. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, September 17th. Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $9.20.

View Our Latest Report on Gossamer Bio

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Gossamer Bio in the first quarter worth approximately $34,000. US Bancorp DE purchased a new position in Gossamer Bio during the third quarter valued at approximately $39,000. Choreo LLC purchased a new position in Gossamer Bio during the second quarter valued at approximately $46,000. Algert Global LLC purchased a new position in Gossamer Bio during the second quarter valued at approximately $75,000. Finally, Sequoia Financial Advisors LLC grew its position in Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after purchasing an additional 20,000 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Stock Performance

GOSS traded down $0.01 on Thursday, hitting $0.89. 546,085 shares of the company’s stock were exchanged, compared to its average volume of 1,454,284. The firm has a market cap of $201.32 million, a PE ratio of -2.24 and a beta of 1.96. Gossamer Bio has a twelve month low of $0.46 and a twelve month high of $1.60. The company has a current ratio of 8.21, a quick ratio of 8.21 and a debt-to-equity ratio of 2.42. The stock has a fifty day moving average of $0.94 and a two-hundred day moving average of $0.86.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million during the quarter, compared to analyst estimates of $160.00 million. On average, research analysts anticipate that Gossamer Bio will post -0.33 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Featured Stories